Bevacizumab-Induced Cutaneous Lupus Erythematosus in a Patient With Metastatic Colon Carcinoma: A Case Report
Sethi Ashish, Moses Raj, Eric Zhuang

TL;DR
A patient with colon cancer developed cutaneous lupus after bevacizumab treatment, which improved after stopping chemotherapy.
Contribution
Reports a rare case of bevacizumab-induced cutaneous lupus and highlights the importance of timely intervention.
Findings
Bevacizumab can cause cutaneous lupus as a rare side effect.
Discontinuation of chemotherapy led to improvement in the patient's condition.
Early recognition and intervention are crucial for managing this adverse reaction.
Abstract
Bevacizumab, an anti-vascular epidermal growth factor inhibitor, is approved for the treatment of various cancers. Hypertension, gastrointestinal perforation, bleeding manifestations, impaired wound healing, and cerebrovascular accidents are common side effects associated with the monoclonal antibody. Uncommon cutaneous reactions like exfoliative dermatitis associated with bevacizumab have been documented in the medical literature. We present an unusual case of bevacizumab-induced cutaneous lupus in a patient with metastatic colon cancer that started resolving after discontinuing chemotherapy. Timely intervention was key in preventing the progression of this chemotherapy-induced cutaneous lupus.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsColorectal Cancer Treatments and Studies · Cancer Treatment and Pharmacology · Chronic Lymphocytic Leukemia Research
